Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
This trial is dedicated to all people living with ALS, their families, and friends. Your partnership in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS.

This breakthrough trial would not be possible without your participation.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality.

Thank You
Navigating Clinical Trial Opportunities

- ClinicalTrials.gov – [clinicaltrials.gov/](http://clinicaltrials.gov/)
- ALS TDI Trial Navigator – [www.als.net/als-trial-navigator/](http://www.als.net/als-trial-navigator/)
- NEALS – [neals.org/als-trials/neals-affiliated](http://neals.org/als-trials/neals-affiliated)
- MDA – [www.mda.org/research/clinical-trials](http://www.mda.org/research/clinical-trials)
- ALSA – [www.als.org/research/finding-als-research-opportunities](http://www.als.org/research/finding-als-research-opportunities)
- International Alliance of ALS/MND Associations – [www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/](http://www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/)
Educational Webinar Opportunities

Visit the NEALS website to explore upcoming webinars or view previous recordings

https://bit.ly/3S4P0Sb

April 25, 2024 / 1:00 pm–2:00 pm

Constipation in People Living with ALS: Does Autonomic Dysfunction Play A Role?

Join us for an insightful session with Dr. Ghazala Hayat, MD, FAAN, FANA, FAANEM, as we delve into the prevalence and challenges of constipation in People Living with ALS. Dr. Hayat will discuss how constipation might be connected to...

May 8, 2024 / 4:00 pm–5:00 pm

An Overview of The ALS Better Care Act

Join Dr. Terry Heiman-Patterson, Dr. Kelly Gwathmey and Dr. Sabrina Paganoni, and as they discuss the importance of multidisciplinary care and the role of the ALS Better Care Act to ensure that quality care at Multidisciplinary Centers...

May 16, 2024 / 11:00 am–12:00 pm

Access for ALL in ALS (ALL ALS) Consortium

National Institutes of Health (NIH) funded “ALL ALS” consortium is a multi-institutional effort that aims to organize the ALS clinical research landscape in the US. ALL ALS is operating in partnership with several stakeholders...
EAP Webpages and Resources

Link to EAP Website:

https://bit.ly/3uni3lc
EAP Webpages and Resources

EAP Opportunities:

The RAPA-501 Expanded Access Protocol (EAP) will be made available to 40 people with ALS at up to 10 US research centers. As per the ACT for ALS law, all EAP participants need to be ineligible for other ongoing clinical trials. This EAP is a unique opportunity for people with ALS to gain access to an investigational product (IP) and contribute to clinical research.

RAPA-501 is simultaneously being studied in the RAPA-501 Phase 2/3 Expansion Cohort. The RAPA-501 EAP will provide real-world data to supplement the RAPA-501 clinical development program.

This EAP will be conducted with the same scientific rigor as a traditional clinical trial, and the data collected will be reported as per NIH and FDA requirements.

Expanded Access Opportunities

NIH-Funded Multicenter Expanded Access Protocols led by the Healey & AMG Center for ALS

RAPA-501 EAP, by Rapa Therapeutics

In people with ALS, the body’s immune system becomes imbalanced and appears to hasten the loss of motor neurons in the brain and spinal cord. Regulatory T-cells help reduce inflammation and could lead to a more balanced immune system in people with ALS. The goal of this study is to reduce neuroinflammation, potentially slowing ALS progression, using specially prepared regulatory T-cells, called RAPA-501 cells. RAPA-501 cells are created through a series of steps: first taking the participant’s own blood through a specialized IV (apheresis), then isolating regulatory T-cells from the blood. Next, these regulatory T-cells are grown under special conditions in a petri dish, becoming RAPA-501 cells. The RAPA-501 cells are then returned to the participant through an intravenous infusion. Prior to the IV infusion of RAPA-501 cells, a low dose of chemotherapy is given to reduce the body's immune response and potentially heighten the effects of the RAPA-501 cells.

View the RAPA-501 EAP on ClinicalTrials.gov

Download the RAPA-501 EAP Brochure
EAP Webpages and Resources

Common Questions:

EAP Webpages and Resources

EAP News & Webinars:

https://bit.ly/43GuegQ
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:

ALS Link sign-up:

https://bit.ly/3r6Nd2L

https://bit.ly/3o2Ds3m

Upcoming Webinars:

April 25th- Weekly Q&A webinar
May 2nd- Weekly Q&A webinar
May 9th- EAP Discussion with Shawn Sarbacker from Tech vs ALS